Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with ER+/HER2- advanced breast cancer as first-line treatment.
CONCLUSIONS: The addition of palbociclib to letrozole was associated with increased efficacy without negatively impacting pain severity or pain interference with daily activities.
PMID: 26894413 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | HER2 | Oral Cancer | Pain | Research | Statistics | Study | Women